Jubilant Life Sciences Q3 Review - CMO Outlook Bright; Radiopharma In Gradual Recovery Mode: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Jubilant Life Sciences Ltd. delivered higher-than-expected Q3 FY21 earnings, led by better traction in -
1. the contract manufacturing organization / generics category of the pharma segment and
2. nutritional products in the life science ingredient (LSI) business.
Post the demerger of LSI with Jubilant Ingrevia from February 01, 2021, the segment is classified as ‘discontinued operations’; the company has been renamed Jubilant Pharmova, which would now comprise the specialty pharma, CMO, generics, contract research and development, and drug discovery businesses.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.